Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients

International Immunopharmacology

Volumn 44, Issue , 2017, Pages 153-159

  Li, Xiuzhong ^a   Chen, Yanqing ^a   Liu, Xu ^a   Zhang, Jin ^a   He, Xu ^a   Teng, Guodong ^a   Yu, Dazhi ^a  

^a 401 Hospital of PLA   (China)

Author keywords

Gal9; Osteosarcoma; Tim3

Indexed keywords

ECALECTIN; GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 10; INTERLEUKIN 12; CYTOKINE; GALECTIN; HAVCR2 PROTEIN, HUMAN; LGALS9 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MONOCYTE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; ADOLESCENT; ADULT; BONE TUMOR; CELL CULTURE; CHILD; COCULTURE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGICAL FEEDBACK; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CELLS, CULTURED; CHILD; COCULTURE TECHNIQUES; CYTOKINES; FEEDBACK, PHYSIOLOGICAL; FEMALE; GALECTINS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; MONOCYTES; OSTEOSARCOMA; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; YOUNG ADULT;

EID: 85009384684     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.01.006     Document Type: Article

References (23)

1. [1] Ottaviani, G., Jaffe, N., The epidemiology of osteosarcoma. Cancer Treat. Res. 152 (2009), 3–13, 10.1007/978-1-4419-0284-9_1.
2. [2] Kansara, M., Teng, M.W., Smyth, M.J., Thomas, D.M., Translational biology of osteosarcoma. Nat. Rev. Cancer 14 (2014), 722–735, 10.1038/nrc3838.
3. [3] Walsh, M.C., Kim, N., Kadono, Y., Rho, J., Lee, S.Y., Lorenzo, J., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24 (2006), 33–63, 10.1146/annurev.immunol.24.021605.090646.
4. [4] Chou, A.J., Kleinerman, E.S., Krailo, M.D., Chen, Z., Betcher, D.L., Healey, J.H., et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 115 (2009), 5339–5348, 10.1002/cncr.24566.
5. [5] Chen, L., Han, X., Ishida, Y., Agata, Y., Shibahara, K., Honjo, T., et al. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125 (2015), 3384–3391, 10.1172/JCI80011.
6. [6] Monney, L., a Sabatos, C., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415 (2002), 536–541, 10.1038/415536a.
7. [7] Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6 (2005), 1245–1252, 10.1038/ni1271.
8. [8] Sabatos, C.A., Chakravarti, S., Cha, E., Schubart, A., Sánchez-Fueyo, A., Zheng, X.X., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4 (2003), 1102–1110, 10.1038/ni988.
9. [9] Sánchez-Fueyo, A., Tian, J., Picarella, D., Domenig, C., Zheng, X.X., a Sabatos, C., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4 (2003), 1093–1101, 10.1038/ni987.
10. [10] Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I.F., Sander, C., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8 + T cell dysfunction in melanoma patients. J. Exp. Med. 207 (2010), 2175–2186, 10.1084/jem.20100637.
11. [11] Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One, 7, 2012, e30676, 10.1371/journal.pone.0030676.
12. [12] Shang, Y., Li, Z., Li, H., Xia, H., Lin, Z., TIM-3 expression in human osteosarcoma: correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol. Lett. 6 (2013), 490–494, 10.3892/ol.2013.1410.
13. [13] Liu, H., Zhi, L., Duan, N., Su, P., Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients. FEBS Open Bio. 6 (2016), 807–815, 10.1002/2211-5463.12079.
14. [14] Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113 (2009), 3821–3830, 10.1182/blood-2008-10-185884.
15. [15] Han, G., Chen, G., Shen, B., Li, Y., Tim-3: an activation marker and activation limiter of innate immune cells. Front. Immunol., 4, 2013, 449, 10.3389/fimmu.2013.00449.
16. [16] Oomizu, S., Arikawa, T., Niki, T., Kadowaki, T., Ueno, M., Nishi, N., et al. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3 + Treg development by galectin-9 secretion. PLoS One, 7, 2012, e48574, 10.1371/journal.pone.0048574.
17. [17] Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep., 6, 2014, 13, 10.12703/P6-13.
18. [18] Zhang, Y., Ma, C.J., Wang, J.M., Ji, X.J., Wu, X.Y., Moorman, J.P., et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14 + monocytes. J. Leukoc. Biol. 91 (2012), 189–196, 10.1189/jlb.1010591.
19. [19] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61, 10.1016/j.immuni.2014.06.010.
20. [20] Anderson, A.C., Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2 (2014), 393–398, 10.1158/2326-6066.CIR-14-0039.
21. [21] Ngiow, S.F., Von Scheidt, B., Akiba, H., Yagita, H., Teng, M.W.L., Smyth, M.J., Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71 (2011), 3540–3551, 10.1158/0008-5472.CAN-11-0096.
22. [22] Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 (2010), 2187–2194, 10.1084/jem.20100643.
23. [23] Jones, R.B., Ndhlovu, L.C., Barbour, J.D., Sheth, P.M., Jha, A.R., Long, B.R., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205 (2008), 2763–2779, 10.1084/jem.20081398.